BVXV — Biondvax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapMomentum Trap
- $23.28m
- $30.30m
BRIEF-Biondvax Receives Supportive Scientific Advice From The Paul Ehrlich Institute For Covid-19 Nanoab Development Plans
NewsBRIEF-Biondvax Announces First Quarter 2022 Financial Results And Provides Business Update
NewsBRIEF-BiondVax Announces Q4 Results
NewsBUZZ-BiondVax rises on deal to develop nanosized antibody therapies
NewsBRIEF-BiondVax Signs Definitive Collaboration Agreement For Development Of Pipeline Of Innovative Nanosized Antibody Therapies
NewsBUZZ-U.S. STOCKS ON THE MOVE-Tencent Music, Baudax Bio, Novavax
NewsBUZZ-U.S. STOCKS ON THE MOVE-LiveOne, Tesla, ADDvantage Technologies
NewsBUZZ-U.S. STOCKS ON THE MOVE-Apple, LiveOne, Tesla
NewsBUZZ-U.S. STOCKS ON THE MOVE-Apple, Flotek Industries, Tesla
NewsBUZZ-BiondVax Pharma surges as former GSK exec joins board
NewsBRIEF-Former CFO Of GSK's Global Vaccines Business Jay Green Joins BiondVax's Board Of Directors
NewsBRIEF-BiondVax Pharmaceuticals Ltd - Announced Pricing Of Underwritten Public Offering Of 3.8 Mln ADSs At Public Offering Price Of $2.36/ADS
NewsBUZZ-BiondVax to develop nanosized COVID-19 antibody therapy, shares gain
NewsBRIEF-Biondvax Pharmaceuticals Ltd Signs Definitive Agreements For Development And Commercialization Of Innovative Nanosized Covid-19 Antibody Therapy
NewsBRIEF-BiondVax Announces Q3 Results And Provides Business Update
NewsBRIEF-BiondVax Advances Its Growth Strategy Towards A New Pipeline Based On Innovative VHH Antibodies
NewsBRIEF-BiondVax Announces Second Quarter 2021 Financial Results And Provides Business Update
NewsBRIEF-Biondvax Pharmaceuticals Posts Quarterly Loss Per Share $0.005
NewsBRIEF-Biondvax Announces Closing Of $12.1 Million Follow-On Underwritten Offering
News